Ovarian cancer (OC) is an aggressive malignancy characterized by a complex
immunosuppressive tumor microenvironment (TME). Immune checkpoint inhibitors have …

Ovarian cancer (OC) is gynecological cancer, and diagnosis and treatment are continuously
advancing. Next-generation sequencing (NGS)-based diagnoses have emerged as novel …

Ovarian cancer, often referred to as the “silent killer,” is notoriously difficult to detect in its
early stages, leading to a poor prognosis for many patients. Diagnosis is often delayed until …

Simple Summary Although immune check point inhibitors have been established as a new
paradigm in cancer treatment, they have shown no clinical benefit in immune excluded or …

The tumor microenvironment (TME) is implicated in tumorigenesis, chemoresistance,
immunotherapy failure and tumor recurrence. Multiple immunosuppressive cells and soluble …

Ovarian cancer (OC) is the third most common gynecological cancer and alone has an
emergence rate of approximately 308,069 cases worldwide (2020) with dire survival rates …

Engineering dendritic cells (DCs) to treat cancer is a long sought-after goal for cell-based
immunotherapies. In this review, we focus on the experience with CMN-001, formally AGS …

Breast cancer is the second most commonly diagnosed cancer in women and the fifth
leading cause of cancer-related deaths worldwide. It is a highly heterogeneous disease …

Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity,
making them ideal candidates for anticancer vaccine development. DC-based …

Nanotechnology has provided an opportunity for unparalleled development of the treatment
of various severe diseases. The unique properties of nanoparticles offer a promising …